| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Dec 2025 |
18 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA |
17 Dec 2025 |
17 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Dec 2025 |
17 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL |
16 Dec 2025 |
16 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 Dec 2025 |
16 Dec 2025 |
001-15170 |
| 4 |
Open Document
|
Open Filing |
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP |
15 Dec 2025 |
11 Dec 2025 |
001-37627 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 Dec 2025 |
15 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION |
12 Dec 2025 |
12 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD |
12 Dec 2025 |
12 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ |
12 Dec 2025 |
12 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Dec 2025 |
12 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION |
11 Dec 2025 |
11 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Dec 2025 |
11 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING APPLICATION |
11 Dec 2025 |
11 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Dec 2025 |
11 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Dec 2025 |
10 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC |
10 Dec 2025 |
10 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Dec 2025 |
09 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 Dec 2025 |
09 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 Dec 2025 |
08 Dec 2025 |
001-15170 |
| SCHEDULE 13D/A |
Open Document
|
Open Filing |
|
05 Dec 2025 |
|
|
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
05 Dec 2025 |
05 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Dec 2025 |
04 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Dec 2025 |
03 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Dec 2025 |
02 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Dec 2025 |
01 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2025 |
01 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
01 Dec 2025 |
01 Dec 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Nov 2025 |
28 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Nov 2025 |
28 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
26 Nov 2025 |
26 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
25 Nov 2025 |
25 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
24 Nov 2025 |
24 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC |
21 Nov 2025 |
21 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
21 Nov 2025 |
21 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 Nov 2025 |
20 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSFER OF TREASURY SHARES |
19 Nov 2025 |
19 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
19 Nov 2025 |
19 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Nov 2025 |
18 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Nov 2025 |
18 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Nov 2025 |
17 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Nov 2025 |
14 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Nov 2025 |
13 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
13 Nov 2025 |
13 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
12 Nov 2025 |
12 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Nov 2025 |
12 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Nov 2025 |
12 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES PROVISIONAL DIVIDEND DATES |
10 Nov 2025 |
10 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Nov 2025 |
10 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Nov 2025 |
07 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
06 Nov 2025 |
06 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
05 Nov 2025 |
05 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Nov 2025 |
04 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Nov 2025 |
03 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Nov 2025 |
03 Nov 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
31 Oct 2025 |
31 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
30 Oct 2025 |
30 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
30 Oct 2025 |
30 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
29 Oct 2025 |
29 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
3RD QUARTER RESULTS |
29 Oct 2025 |
29 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Oct 2025 |
28 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU |
28 Oct 2025 |
28 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
27 Oct 2025 |
27 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA |
24 Oct 2025 |
24 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
24 Oct 2025 |
24 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
23 Oct 2025 |
23 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI |
22 Oct 2025 |
22 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
22 Oct 2025 |
22 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
LATOZINEMAB DATA READ OUT |
22 Oct 2025 |
22 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS |
21 Oct 2025 |
21 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
21 Oct 2025 |
21 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR |
21 Oct 2025 |
21 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 Oct 2025 |
20 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Oct 2025 |
17 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Oct 2025 |
16 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 Oct 2025 |
16 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Oct 2025 |
15 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 Oct 2025 |
15 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA |
14 Oct 2025 |
14 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Oct 2025 |
14 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Oct 2025 |
14 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Oct 2025 |
14 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Oct 2025 |
10 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Oct 2025 |
10 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 Oct 2025 |
09 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 Oct 2025 |
08 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Oct 2025 |
07 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
06 Oct 2025 |
06 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Oct 2025 |
03 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Oct 2025 |
02 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2025 |
01 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
01 Oct 2025 |
01 Oct 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME |
30 Sep 2025 |
30 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK APPOINTS CEO DESIGNATE |
29 Sep 2025 |
29 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Sep 2025 |
22 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
19 Sep 2025 |
19 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Sep 2025 |
18 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK US INVESTMENT ANNOUNCEMENT |
17 Sep 2025 |
17 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Sep 2025 |
17 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 Sep 2025 |
16 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 Sep 2025 |
15 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Sep 2025 |
12 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Sep 2025 |
11 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Sep 2025 |
10 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Sep 2025 |
10 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 Sep 2025 |
09 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 Sep 2025 |
08 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
05 Sep 2025 |
05 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
04 Sep 2025 |
04 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Sep 2025 |
04 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Sep 2025 |
03 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Sep 2025 |
02 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Sep 2025 |
02 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Sep 2025 |
02 Sep 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
29 Aug 2025 |
29 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Aug 2025 |
28 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
27 Aug 2025 |
27 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
26 Aug 2025 |
26 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
22 Aug 2025 |
22 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Aug 2025 |
21 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
21 Aug 2025 |
21 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 Aug 2025 |
20 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Aug 2025 |
19 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
19 Aug 2025 |
19 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Aug 2025 |
18 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 Aug 2025 |
15 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Aug 2025 |
14 Aug 2025 |
001-15170 |
| SCHEDULE 13D |
Open Document
|
Open Filing |
|
13 Aug 2025 |
|
|
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
13 Aug 2025 |
13 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Aug 2025 |
12 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Aug 2025 |
12 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN |
11 Aug 2025 |
11 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Aug 2025 |
11 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT |
08 Aug 2025 |
08 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 Aug 2025 |
08 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Aug 2025 |
07 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
06 Aug 2025 |
06 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
05 Aug 2025 |
05 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Aug 2025 |
04 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2025 |
01 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
01 Aug 2025 |
01 Aug 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
31 Jul 2025 |
31 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
2ND QUARTER RESULTS |
30 Jul 2025 |
30 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
30 Jul 2025 |
30 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
29 Jul 2025 |
29 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS |
28 Jul 2025 |
28 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
PRIMARY DOCUMENT |
28 Jul 2025 |
28 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
25 Jul 2025 |
25 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA |
24 Jul 2025 |
24 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
24 Jul 2025 |
24 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA REVIEW EXTENDED FOR BLENREP |
23 Jul 2025 |
23 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
23 Jul 2025 |
23 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
22 Jul 2025 |
22 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
21 Jul 2025 |
21 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Jul 2025 |
18 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP US ODAC OUTCOME |
18 Jul 2025 |
18 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Jul 2025 |
18 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSKS SHINGRIX FULLY LIQUID FDA APPROVAL |
17 Jul 2025 |
17 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Jul 2025 |
17 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 Jul 2025 |
16 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Jul 2025 |
15 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 Jul 2025 |
15 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Jul 2025 |
14 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA |
14 Jul 2025 |
14 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Jul 2025 |
14 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Jul 2025 |
11 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Jul 2025 |
10 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 Jul 2025 |
09 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 Jul 2025 |
08 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD |
07 Jul 2025 |
07 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Jul 2025 |
07 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Jul 2025 |
07 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Jul 2025 |
03 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Jul 2025 |
02 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2025 |
01 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
01 Jul 2025 |
01 Jul 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
30 Jun 2025 |
30 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
27 Jun 2025 |
27 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
26 Jun 2025 |
26 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
25 Jun 2025 |
25 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Jun 2025 |
24 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
24 Jun 2025 |
24 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
24 Jun 2025 |
24 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Jun 2025 |
23 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
LINERIXIBAT FILE ACCEPTED BY EMA |
23 Jun 2025 |
23 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
23 Jun 2025 |
23 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK |
20 Jun 2025 |
20 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 Jun 2025 |
20 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 Jun 2025 |
20 Jun 2025 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
18 Jun 2025 |
31 Dec 2024 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS |
18 Jun 2025 |
31 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Jun 2025 |
18 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Jun 2025 |
17 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 Jun 2025 |
16 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jun 2025 |
13 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
13 Jun 2025 |
13 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA |
13 Jun 2025 |
13 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jun 2025 |
12 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Jun 2025 |
12 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Jun 2025 |
11 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Jun 2025 |
11 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Jun 2025 |
10 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 Jun 2025 |
09 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
06 Jun 2025 |
06 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
05 Jun 2025 |
05 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME |
04 Jun 2025 |
04 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Jun 2025 |
04 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Jun 2025 |
03 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
02 Jun 2025 |
02 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jun 2025 |
02 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA |
02 Jun 2025 |
02 Jun 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Jun 2025 |
02 Jun 2025 |
001-15170 |
| SD |
Open Document
|
Open Filing |
SPECIALIZED DISCLOSURE REPORT |
30 May 2025 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
30 May 2025 |
30 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
29 May 2025 |
29 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY |
28 May 2025 |
28 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 May 2025 |
28 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
27 May 2025 |
27 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE CHMP OPINION ON BLENREP IN EU |
23 May 2025 |
23 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES NUCALA COPD INDICATION |
23 May 2025 |
23 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
23 May 2025 |
23 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
22 May 2025 |
22 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
21 May 2025 |
21 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 May 2025 |
20 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 May 2025 |
20 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN |
19 May 2025 |
19 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
19 May 2025 |
19 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 May 2025 |
16 May 2025 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
15 May 2025 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 May 2025 |
15 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK TO ACQUIRE EFIMOSFERMIN |
14 May 2025 |
14 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 May 2025 |
14 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 May 2025 |
13 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME |
13 May 2025 |
13 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
13 May 2025 |
13 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
12 May 2025 |
12 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 May 2025 |
12 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 May 2025 |
09 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 May 2025 |
08 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 May 2025 |
08 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL |
08 May 2025 |
08 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 May 2025 |
08 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
07 May 2025 |
07 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 May 2025 |
07 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
06 May 2025 |
06 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 May 2025 |
02 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 May 2025 |
01 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 May 2025 |
01 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM |
01 May 2025 |
01 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
01 May 2025 |
01 May 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
30 Apr 2025 |
30 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
30 Apr 2025 |
30 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
29 Apr 2025 |
29 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Apr 2025 |
28 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
25 Apr 2025 |
25 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
24 Apr 2025 |
24 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
23 Apr 2025 |
23 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
22 Apr 2025 |
22 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP LICENSED BY UK MHRA |
17 Apr 2025 |
17 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Apr 2025 |
17 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS |
17 Apr 2025 |
17 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US |
17 Apr 2025 |
17 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Apr 2025 |
17 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
16 Apr 2025 |
16 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Apr 2025 |
15 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
15 Apr 2025 |
15 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Apr 2025 |
14 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Apr 2025 |
14 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Apr 2025 |
11 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Apr 2025 |
11 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Apr 2025 |
10 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
09 Apr 2025 |
09 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
08 Apr 2025 |
08 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Apr 2025 |
07 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Apr 2025 |
04 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Apr 2025 |
03 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
02 Apr 2025 |
02 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2025 |
01 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
01 Apr 2025 |
01 Apr 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
31 Mar 2025 |
31 Mar 2025 |
001-15170 |
| SCHEDULE 13D/A |
Open Document
|
Open Filing |
|
28 Mar 2025 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Mar 2025 |
28 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Mar 2025 |
28 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
27 Mar 2025 |
27 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
26 Mar 2025 |
26 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK UUTI TREATMENT APPROVED BY US FDA |
25 Mar 2025 |
25 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
25 Mar 2025 |
25 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
24 Mar 2025 |
24 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA FILING ACCEPTANCE FOR NUCALA COPD |
24 Mar 2025 |
24 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
24 Mar 2025 |
24 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Mar 2025 |
21 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
21 Mar 2025 |
21 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
20 Mar 2025 |
20 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
19 Mar 2025 |
19 Mar 2025 |
001-15170 |
| CERT |
Open Document
|
Open Filing |
NYSE CERTIFICATION |
18 Mar 2025 |
|
001-15170 |
| CERT |
Open Document
|
Open Filing |
NYSE CERTIFICATION |
18 Mar 2025 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
18 Mar 2025 |
18 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
17 Mar 2025 |
17 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Mar 2025 |
14 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
14 Mar 2025 |
14 Mar 2025 |
001-15170 |
| 8-A12B |
Open Document
|
Open Filing |
8-A12B |
13 Mar 2025 |
|
001-15170 |
| 8-A12B |
Open Document
|
Open Filing |
8-A12B |
13 Mar 2025 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
6-K |
13 Mar 2025 |
13 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
13 Mar 2025 |
13 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
12 Mar 2025 |
12 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
11 Mar 2025 |
11 Mar 2025 |
001-15170 |
| 424B2 |
Open Document
| Data
|
Open Filing |
424B2 |
10 Mar 2025 |
|
333-278205 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
10 Mar 2025 |
10 Mar 2025 |
001-15170 |
| SCHEDULE 13G/A |
Open Document
|
Open Filing |
|
07 Mar 2025 |
|
005-84251 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
07 Mar 2025 |
07 Mar 2025 |
001-15170 |
| FWP |
Open Document
|
Open Filing |
FWP |
07 Mar 2025 |
|
333-278205 |
| 424B2 |
Open Document
|
Open Filing |
424B2 |
06 Mar 2025 |
|
333-278205 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
06 Mar 2025 |
06 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
05 Mar 2025 |
05 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
04 Mar 2025 |
04 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PLC 2024 ANNUAL REPORT ON FORM 20-F |
03 Mar 2025 |
03 Mar 2025 |
001-15170 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
03 Mar 2025 |
|
001-15170 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
03 Mar 2025 |
31 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Mar 2025 |
03 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS |
03 Mar 2025 |
03 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ANCHOR RESULTS PRESENTED AT 2025 AAAAI |
03 Mar 2025 |
03 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
03 Mar 2025 |
03 Mar 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
28 Feb 2025 |
28 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
27 Feb 2025 |
27 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES ANNUAL REPORT 2024 |
27 Feb 2025 |
27 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Feb 2025 |
26 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
26 Feb 2025 |
26 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSACTION IN OWN SHARES |
25 Feb 2025 |
25 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES ACQUISITION OF IDRX, INC. |
24 Feb 2025 |
24 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PLC COMMENCES SHARE BUYBACK PROGRAMME |
24 Feb 2025 |
24 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Feb 2025 |
21 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA COPD SUBMISSION ACCEPTED IN CHINA |
20 Feb 2025 |
20 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA |
18 Feb 2025 |
18 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Feb 2025 |
13 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Feb 2025 |
11 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
05 Feb 2025 |
05 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Feb 2025 |
03 Feb 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN |
28 Jan 2025 |
28 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB |
28 Jan 2025 |
28 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION |
27 Jan 2025 |
27 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI EXPANDED APPROVAL IN THE EU |
21 Jan 2025 |
21 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Jan 2025 |
16 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Jan 2025 |
15 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Jan 2025 |
14 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jan 2025 |
13 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. |
13 Jan 2025 |
13 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW |
10 Jan 2025 |
10 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION |
07 Jan 2025 |
07 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP |
03 Jan 2025 |
03 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jan 2025 |
02 Jan 2025 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Dec 2024 |
23 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING APPLICATION |
20 Dec 2024 |
20 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
HEADLINE RESULTS FROM PHASE III FIRST TRIAL |
20 Dec 2024 |
20 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION |
16 Dec 2024 |
16 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA GRANTS PRIME DESIGNATION FOR GSK 227 |
16 Dec 2024 |
16 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI RECEIVES POSITIVE CHMP OPINION |
16 Dec 2024 |
16 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Dec 2024 |
12 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
OVERALL SURVIVAL DATA PRESENTED FOR BLENREP |
09 Dec 2024 |
09 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP COMBINATION CHINA FILING ACCEPTANCE |
09 Dec 2024 |
09 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA COPD SUBMISSION ACCEPTED BY US FDA |
09 Dec 2024 |
09 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED |
05 Dec 2024 |
05 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
02 Dec 2024 |
02 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Dec 2024 |
02 Dec 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU |
27 Nov 2024 |
27 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW |
25 Nov 2024 |
25 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 |
22 Nov 2024 |
22 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Nov 2024 |
19 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT |
19 Nov 2024 |
19 Nov 2024 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO THE SCHEDULE 13D |
15 Nov 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP |
14 Nov 2024 |
14 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
13 Nov 2024 |
13 Nov 2024 |
001-15170 |
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13G |
12 Nov 2024 |
|
005-84251 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Nov 2024 |
12 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES |
12 Nov 2024 |
12 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2024 |
01 Nov 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
30 Oct 2024 |
30 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
3RD QUARTER RESULTS |
30 Oct 2024 |
30 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK |
24 Oct 2024 |
24 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Oct 2024 |
17 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Oct 2024 |
16 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN |
16 Oct 2024 |
16 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Oct 2024 |
15 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB |
15 Oct 2024 |
15 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Oct 2024 |
11 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Oct 2024 |
10 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS |
09 Oct 2024 |
09 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS |
08 Oct 2024 |
08 Oct 2024 |
001-15170 |
| 4 |
Open Document
|
Open Filing |
WVE - CHANGE IN BENEFICIAL OWNERSHIP |
01 Oct 2024 |
27 Sep 2024 |
001-37627 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2024 |
01 Oct 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Sep 2024 |
24 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE |
24 Sep 2024 |
24 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
18 Sep 2024 |
18 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA |
17 Sep 2024 |
17 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP |
13 Sep 2024 |
13 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Sep 2024 |
12 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA |
12 Sep 2024 |
12 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
11 Sep 2024 |
11 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CHANGE OF REGISTERED OFFICE |
11 Sep 2024 |
11 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL |
11 Sep 2024 |
11 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS |
09 Sep 2024 |
09 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 Sep 2024 |
06 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE PHASE III RESULTS FOR NUCALA IN COPD |
06 Sep 2024 |
06 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Sep 2024 |
03 Sep 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA APPROVAL ON AREXVY FOR 50-59 AT RISK |
29 Aug 2024 |
29 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP |
28 Aug 2024 |
28 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN |
28 Aug 2024 |
28 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
28 Aug 2024 |
28 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Aug 2024 |
21 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Aug 2024 |
20 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION |
20 Aug 2024 |
20 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
16 Aug 2024 |
16 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Aug 2024 |
12 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
06 Aug 2024 |
06 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA EXPANDS JEMPERLI APPROVAL |
02 Aug 2024 |
02 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2024 |
01 Aug 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
2ND QUARTER RESULTS |
31 Jul 2024 |
31 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
29 Jul 2024 |
29 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK |
29 Jul 2024 |
29 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP EMA FILING ACCEPTANCE |
19 Jul 2024 |
19 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Jul 2024 |
18 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Jul 2024 |
16 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Jul 2024 |
15 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jul 2024 |
12 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK AND CUREVAC COLLABORATION RESTRUCTURED |
03 Jul 2024 |
03 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2024 |
01 Jul 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
28 Jun 2024 |
28 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA VALIDATES JEMPERLI MARKETING AUTHORISATION |
24 Jun 2024 |
24 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS |
24 Jun 2024 |
24 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Jun 2024 |
21 Jun 2024 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
18 Jun 2024 |
31 Dec 2023 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
18 Jun 2024 |
31 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jun 2024 |
12 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
11 Jun 2024 |
11 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
10 Jun 2024 |
10 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK |
10 Jun 2024 |
10 Jun 2024 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
03 Jun 2024 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jun 2024 |
03 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE |
03 Jun 2024 |
03 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS |
03 Jun 2024 |
03 Jun 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
03 Jun 2024 |
03 Jun 2024 |
001-15170 |
| SD |
Open Document
|
Open Filing |
SPECIALIZED DISCLOSURE REPORT |
31 May 2024 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
24 May 2024 |
24 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB |
21 May 2024 |
21 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 May 2024 |
20 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CURRENT REPORT |
17 May 2024 |
17 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
17 May 2024 |
17 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 May 2024 |
14 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
13 May 2024 |
13 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
08 May 2024 |
08 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGE |
08 May 2024 |
08 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
03 May 2024 |
03 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
01 May 2024 |
01 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 May 2024 |
01 May 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI |
24 Apr 2024 |
24 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Apr 2024 |
19 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Apr 2024 |
17 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX |
17 Apr 2024 |
17 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS |
17 Apr 2024 |
17 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
AMENDMENT - DIRECTOR/PDMR SHAREHOLDING |
16 Apr 2024 |
16 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE |
16 Apr 2024 |
16 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Apr 2024 |
15 Apr 2024 |
001-15170 |
| 6-K/A |
Open Document
|
Open Filing |
REPLACEMENT - TOTAL VOTING RIGHTS |
04 Apr 2024 |
04 Apr 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Apr 2024 |
02 Apr 2024 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
28 Mar 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Mar 2024 |
26 Mar 2024 |
001-15170 |
| F-3ASR |
Open Document
|
Open Filing |
F-3ASR |
25 Mar 2024 |
|
333-278205 |
| 6-K |
Open Document
|
Open Filing |
NOTICE OF AGM |
25 Mar 2024 |
25 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSFER OF TREASURY SHARES |
22 Mar 2024 |
22 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Mar 2024 |
22 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER |
18 Mar 2024 |
18 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Mar 2024 |
13 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGE |
08 Mar 2024 |
08 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS |
07 Mar 2024 |
07 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED |
06 Mar 2024 |
06 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNUAL REPORT 2023 ON FORM 20 F |
05 Mar 2024 |
05 Mar 2024 |
001-15170 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
05 Mar 2024 |
|
001-15170 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
05 Mar 2024 |
31 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING |
05 Mar 2024 |
05 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2024 |
01 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES ANNUAL REPORT 2023 |
01 Mar 2024 |
01 Mar 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
29 Feb 2024 |
29 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
29 Feb 2024 |
29 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Feb 2024 |
26 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS |
26 Feb 2024 |
26 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Feb 2024 |
22 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED |
21 Feb 2024 |
21 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Feb 2024 |
20 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Feb 2024 |
15 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES ACQUISITION OF AIOLOS BIO |
15 Feb 2024 |
15 Feb 2024 |
001-15170 |
| SC 13G/A |
Open Document
|
Open Filing |
SC 13G/A |
13 Feb 2024 |
|
005-84251 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Feb 2024 |
13 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Feb 2024 |
13 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Feb 2024 |
13 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Feb 2024 |
12 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Feb 2024 |
12 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Feb 2024 |
12 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN |
12 Feb 2024 |
12 Feb 2024 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO SC 13D |
09 Feb 2024 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13G |
06 Feb 2024 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13G |
06 Feb 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
06 Feb 2024 |
06 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED |
06 Feb 2024 |
06 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA |
06 Feb 2024 |
06 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Feb 2024 |
01 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2024 |
01 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
01 Feb 2024 |
01 Feb 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
31 Jan 2024 |
31 Jan 2024 |
001-15170 |
| 4 |
Open Document
|
Open Filing |
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP |
30 Jan 2024 |
07 Dec 2023 |
001-37627 |
| 6-K |
Open Document
|
Open Filing |
EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
29 Jan 2024 |
29 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU |
29 Jan 2024 |
29 Jan 2024 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
19 Jan 2024 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Jan 2024 |
19 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Jan 2024 |
17 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CURRENT REPORT |
17 Jan 2024 |
16 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
17 Jan 2024 |
17 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Jan 2024 |
16 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA |
10 Jan 2024 |
10 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO |
09 Jan 2024 |
09 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Jan 2024 |
02 Jan 2024 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Dec 2023 |
21 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT |
18 Dec 2023 |
18 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Dec 2023 |
13 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS |
12 Dec 2023 |
11 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION |
11 Dec 2023 |
11 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES |
04 Dec 2023 |
04 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2023 |
01 Dec 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING APPLICATION |
30 Nov 2023 |
30 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
29 Nov 2023 |
29 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS |
27 Nov 2023 |
27 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Nov 2023 |
21 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
15 Nov 2023 |
15 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Nov 2023 |
13 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB |
13 Nov 2023 |
13 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2023 |
01 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
3RD QUARTER RESULTS |
01 Nov 2023 |
01 Nov 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT |
30 Oct 2023 |
30 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA |
26 Oct 2023 |
26 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Oct 2023 |
25 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NEW DATA FOR AREXVY, GSK'S RSV VACCINE |
25 Oct 2023 |
25 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Oct 2023 |
20 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Oct 2023 |
18 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Oct 2023 |
17 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION |
16 Oct 2023 |
16 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Oct 2023 |
13 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2023 |
12 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ZANTAC (RANITIDINE) LITIGATION |
11 Oct 2023 |
11 Oct 2023 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
10 Oct 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP |
10 Oct 2023 |
10 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CURRENT REPORT |
06 Oct 2023 |
06 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
06 Oct 2023 |
06 Oct 2023 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
02 Oct 2023 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Oct 2023 |
02 Oct 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
27 Sep 2023 |
27 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN |
25 Sep 2023 |
25 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Sep 2023 |
21 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
APRETUDE FOR PREP RECEIVES EMA APPROVAL |
19 Sep 2023 |
19 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES OJJAARA (MOMELOTINIB) |
18 Sep 2023 |
18 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Sep 2023 |
13 Sep 2023 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
11 Sep 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Sep 2023 |
11 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
MOMELOTINIB FILING ACCEPTED IN JAPAN |
11 Sep 2023 |
11 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 Sep 2023 |
06 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2023 |
01 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN |
01 Sep 2023 |
01 Sep 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
31 Aug 2023 |
31 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
31 Aug 2023 |
31 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Aug 2023 |
25 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Aug 2023 |
23 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA |
23 Aug 2023 |
23 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Aug 2023 |
22 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Aug 2023 |
10 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Aug 2023 |
09 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2023 |
01 Aug 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO |
31 Jul 2023 |
31 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
31 Jul 2023 |
31 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Jul 2023 |
28 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
2ND QUARTER RESULTS |
26 Jul 2023 |
26 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP |
24 Jul 2023 |
24 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Jul 2023 |
20 Jul 2023 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
20 Jul 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Jul 2023 |
17 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jul 2023 |
13 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jul 2023 |
03 Jul 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES ACQUISITION OF BELLUS HEALTH |
28 Jun 2023 |
28 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE |
27 Jun 2023 |
27 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION |
26 Jun 2023 |
26 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER |
26 Jun 2023 |
26 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Jun 2023 |
23 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Jun 2023 |
23 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Jun 2023 |
23 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
23 Jun 2023 |
23 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSKS AREXVY RECOMMENDED BY ACIP |
22 Jun 2023 |
22 Jun 2023 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT |
21 Jun 2023 |
31 Dec 2022 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
21 Jun 2023 |
31 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE |
21 Jun 2023 |
21 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB |
16 Jun 2023 |
16 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jun 2023 |
12 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EU AUTHORISATION OF GSKS RSV VACCINE AREXVY |
07 Jun 2023 |
07 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI |
06 Jun 2023 |
06 Jun 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jun 2023 |
01 Jun 2023 |
001-15170 |
| SD |
Open Document
|
Open Filing |
SPECIALIZED DISCLOSURE |
30 May 2023 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 May 2023 |
22 May 2023 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
16 May 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 May 2023 |
15 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
15 May 2023 |
15 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 May 2023 |
12 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
MENABCWY VACCINE PRELIMINARY PHASE III RESULTS |
12 May 2023 |
12 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA |
12 May 2023 |
12 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
12 May 2023 |
12 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CURRENT REPORT OF FOREIGN ISSUER |
12 May 2023 |
11 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 May 2023 |
09 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
04 May 2023 |
04 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
03 May 2023 |
03 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS |
03 May 2023 |
03 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 May 2023 |
02 May 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Apr 2023 |
28 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION |
27 Apr 2023 |
27 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
26 Apr 2023 |
26 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION |
25 Apr 2023 |
25 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Apr 2023 |
20 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Apr 2023 |
19 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC |
18 Apr 2023 |
18 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Apr 2023 |
17 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GEPOTIDACIN POSITIVE PHASE III DATA |
17 Apr 2023 |
17 Apr 2023 |
001-15170 |
| 20-F/A |
Open Document
| Data
|
Open Filing |
20-F/A |
17 Apr 2023 |
31 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Apr 2023 |
03 Apr 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI |
28 Mar 2023 |
28 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
PUBLICATION OF 2023 AGM NOTICE |
27 Mar 2023 |
27 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
24 Mar 2023 |
24 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Mar 2023 |
21 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Mar 2023 |
20 Mar 2023 |
001-15170 |
| EFFECT |
Open Document
|
Open Filing |
|
15 Mar 2023 |
|
333-254756 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE |
14 Mar 2023 |
14 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA NDA ACCEPTED FOR REVIEW IN CHINA |
14 Mar 2023 |
14 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Mar 2023 |
13 Mar 2023 |
001-15170 |
| POS AM |
Open Document
|
Open Filing |
POS AM |
10 Mar 2023 |
|
333-254756 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNUAL REPORT 2022 ON FORM 20-F |
10 Mar 2023 |
10 Mar 2023 |
001-15170 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
10 Mar 2023 |
|
001-15170 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
10 Mar 2023 |
31 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES ANNUAL REPORT 2022 |
10 Mar 2023 |
10 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE |
02 Mar 2023 |
02 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2023 |
01 Mar 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
27 Feb 2023 |
27 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Feb 2023 |
23 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA |
23 Feb 2023 |
23 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Feb 2023 |
22 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL |
16 Feb 2023 |
16 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Feb 2023 |
15 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Feb 2023 |
15 Feb 2023 |
001-15170 |
| SC 13G/A |
Open Document
|
Open Filing |
SC 13G/A |
14 Feb 2023 |
|
005-84251 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Feb 2023 |
14 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Feb 2023 |
14 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Feb 2023 |
14 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Feb 2023 |
14 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Feb 2023 |
10 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL |
10 Feb 2023 |
10 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI FDA ODAC POSITIVE OUTCOME |
10 Feb 2023 |
10 Feb 2023 |
001-15170 |
| SC 13G |
Open Document
|
Open Filing |
SCHEDULE 13G |
06 Feb 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD |
02 Feb 2023 |
02 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Feb 2023 |
01 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2023 |
01 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA |
01 Feb 2023 |
01 Feb 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
01 Feb 2023 |
01 Feb 2023 |
001-15170 |
| SC 13G |
Open Document
|
Open Filing |
SCHEDULE 13G |
30 Jan 2023 |
|
|
| 3 |
Open Document
|
Open Filing |
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP |
30 Jan 2023 |
23 Jan 2023 |
001-37627 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
20 Jan 2023 |
|
|
| SC 13D/A |
Open Document
|
Open Filing |
SCHEDULE 13D/A |
20 Jan 2023 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Jan 2023 |
18 Jan 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Jan 2023 |
17 Jan 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Jan 2023 |
17 Jan 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jan 2023 |
13 Jan 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jan 2023 |
12 Jan 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Jan 2023 |
03 Jan 2023 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Dec 2022 |
22 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Dec 2022 |
21 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Dec 2022 |
21 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD AND COMMITTEE CHANGES |
15 Dec 2022 |
15 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Dec 2022 |
13 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
07 Dec 2022 |
07 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRANSFER OF TREASURY SHARES |
05 Dec 2022 |
05 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
02 Dec 2022 |
02 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER |
02 Dec 2022 |
02 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA FILE ACCEPTED FOR MOMELOTINIB |
02 Dec 2022 |
02 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2022 |
01 Dec 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES |
25 Nov 2022 |
25 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLENREP US UPDATE |
22 Nov 2022 |
22 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Nov 2022 |
21 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
15 Nov 2022 |
15 Nov 2022 |
001-15170 |
| 3 |
Open Document
|
Open Filing |
|
14 Nov 2022 |
07 Nov 2022 |
001-38266 |
| SC 13D/A |
Open Document
|
Open Filing |
SCHEDULE 13D/A |
14 Nov 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
GSK UPDATE: ZEJULA 2L IN US |
14 Nov 2022 |
14 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU |
10 Nov 2022 |
10 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Nov 2022 |
10 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING APPLICATION |
10 Nov 2022 |
10 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DREAMM-3 PHASE III TRIAL FOR BLENREP |
07 Nov 2022 |
07 Nov 2022 |
001-15170 |
| 3 |
Open Document
|
Open Filing |
ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP |
04 Nov 2022 |
16 Jun 2021 |
001-39587 |
| SC 13D |
Open Document
|
Open Filing |
ACQUISITION OF BENEFICIAL OWNERSHIP |
04 Nov 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP |
03 Nov 2022 |
03 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
3RD QUARTER RESULTS |
02 Nov 2022 |
02 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK RSV VACCINE: US FDA PRIORITY REVIEW |
02 Nov 2022 |
02 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2022 |
01 Nov 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW |
28 Oct 2022 |
28 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP |
28 Oct 2022 |
28 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT |
27 Oct 2022 |
27 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE |
27 Oct 2022 |
27 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGES |
25 Oct 2022 |
25 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN |
21 Oct 2022 |
21 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
MENVEO NEW SINGLE-VIAL APPROVED BY US FDA |
17 Oct 2022 |
17 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Oct 2022 |
14 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Oct 2022 |
13 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Oct 2022 |
13 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Oct 2022 |
13 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE |
13 Oct 2022 |
13 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2022 |
12 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION |
11 Oct 2022 |
11 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
07 Oct 2022 |
07 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
07 Oct 2022 |
07 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 Oct 2022 |
03 Oct 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
30 Sep 2022 |
30 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Sep 2022 |
26 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK CHIEF FINANCIAL OFFICER SUCCESSION |
26 Sep 2022 |
26 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL |
22 Sep 2022 |
22 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM |
22 Sep 2022 |
22 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
21 Sep 2022 |
21 Sep 2022 |
001-15170 |
| 4 |
Open Document
|
Open Filing |
|
20 Sep 2022 |
16 Sep 2022 |
001-36033 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
20 Sep 2022 |
|
|
| 25-NSE |
Open Document
|
Open Filing |
|
15 Sep 2022 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Sep 2022 |
13 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Sep 2022 |
08 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT |
06 Sep 2022 |
06 Sep 2022 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
01 Sep 2022 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2022 |
01 Sep 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK BOARD CHANGES |
24 Aug 2022 |
24 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Aug 2022 |
22 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB |
17 Aug 2022 |
17 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE |
17 Aug 2022 |
17 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. |
16 Aug 2022 |
16 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
12 Aug 2022 |
12 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Aug 2022 |
11 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Aug 2022 |
10 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CURRENT REPORT OF FOREIGN ISSUER |
03 Aug 2022 |
03 Aug 2022 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
03 Aug 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Aug 2022 |
01 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Aug 2022 |
01 Aug 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
29 Jul 2022 |
29 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK BOARD CHANGE |
29 Jul 2022 |
29 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Jul 2022 |
28 Jul 2022 |
001-15170 |
| SC 13D |
Open Document
|
Open Filing |
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP |
27 Jul 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
2ND QUARTER RESULTS |
27 Jul 2022 |
27 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
HOLDING(S) IN COMPANY |
22 Jul 2022 |
22 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD AND COMMITTEE CHANGES |
22 Jul 2022 |
22 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
COMPLETION OF GSK SHARE CONSOLIDATION |
18 Jul 2022 |
18 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION |
18 Jul 2022 |
18 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jul 2022 |
12 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Jul 2022 |
08 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Jul 2022 |
08 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Jul 2022 |
08 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Jul 2022 |
08 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
08 Jul 2022 |
08 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF GENERAL MEETING |
06 Jul 2022 |
06 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
06 Jul 2022 |
06 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 |
05 Jul 2022 |
05 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
05 Jul 2022 |
05 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
05 Jul 2022 |
05 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2022 |
01 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY |
01 Jul 2022 |
01 Jul 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Jun 2022 |
28 Jun 2022 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
28 Jun 2022 |
31 Dec 2021 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
28 Jun 2022 |
31 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN |
28 Jun 2022 |
28 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
27 Jun 2022 |
27 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Jun 2022 |
24 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Jun 2022 |
16 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE |
10 Jun 2022 |
10 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Jun 2022 |
09 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
07 Jun 2022 |
07 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US FDA APPROVAL OF PRIORIX |
06 Jun 2022 |
06 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
6-K |
01 Jun 2022 |
01 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DEMERGER UPDATE: PUBLICATION OF DOCUMENTS |
01 Jun 2022 |
01 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA |
01 Jun 2022 |
01 Jun 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK TO ACQUIRE AFFINIVAX, INC. |
31 May 2022 |
31 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD |
31 May 2022 |
31 May 2022 |
001-15170 |
| SD |
Open Document
|
Open Filing |
SPECIALIZED DISCLOSURE |
27 May 2022 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA |
27 May 2022 |
26 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 May 2022 |
25 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
23 May 2022 |
23 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
IAIN MACKAY - EXTERNAL APPOINTMENT |
19 May 2022 |
19 May 2022 |
001-15170 |
| 424B3 |
Open Document
|
Open Filing |
424B3 |
17 May 2022 |
|
333-264759 |
| 424B3 |
Open Document
|
Open Filing |
424B3 |
17 May 2022 |
|
333-232726 |
| 6-K |
Open Document
|
Open Filing |
CHANGE OF NAME TO GSK PLC |
16 May 2022 |
16 May 2022 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
13 May 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 May 2022 |
13 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 May 2022 |
12 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
11 May 2022 |
11 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 May 2022 |
09 May 2022 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
09 May 2022 |
|
001-15170 |
| F-6EF |
Open Document
|
Open Filing |
F-6 |
06 May 2022 |
|
333-264759 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
04 May 2022 |
04 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
04 May 2022 |
04 May 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
03 May 2022 |
03 May 2022 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
02 May 2022 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
27 Apr 2022 |
27 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Apr 2022 |
26 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA |
19 Apr 2022 |
19 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Apr 2022 |
14 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Apr 2022 |
14 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Apr 2022 |
14 Apr 2022 |
001-15170 |
| DFAN14A |
Open Document
|
Open Filing |
DFAN14A |
13 Apr 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Apr 2022 |
13 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Apr 2022 |
13 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN |
13 Apr 2022 |
13 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Apr 2022 |
12 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Apr 2022 |
12 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Apr 2022 |
12 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Apr 2022 |
12 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Apr 2022 |
01 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES |
01 Apr 2022 |
01 Apr 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
PUBLICATION OF 2022 AGM NOTICE |
28 Mar 2022 |
28 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Mar 2022 |
24 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL |
24 Mar 2022 |
24 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Mar 2022 |
23 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ISSUANCE OF NOTES |
23 Mar 2022 |
23 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Mar 2022 |
16 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Mar 2022 |
15 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
APPOINTMENTS TO DESIGNATE HALEON BOARD |
15 Mar 2022 |
15 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Mar 2022 |
11 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Mar 2022 |
09 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNUAL REPORT 2021 ON FORM 20-F |
08 Mar 2022 |
08 Mar 2022 |
001-15170 |
| IRANNOTICE |
Open Document
|
Open Filing |
IRANNOTICE |
08 Mar 2022 |
|
001-15170 |
| 20-F |
Open Document
| Data
|
Open Filing |
20-F |
08 Mar 2022 |
31 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES ANNUAL REPORT 2021 |
04 Mar 2022 |
04 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Mar 2022 |
01 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Mar 2022 |
01 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
01 Mar 2022 |
01 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA |
01 Mar 2022 |
01 Mar 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FOMR 6-K |
28 Feb 2022 |
28 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FORM 6-K |
28 Feb 2022 |
28 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Feb 2022 |
24 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE |
24 Feb 2022 |
24 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Feb 2022 |
23 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Feb 2022 |
22 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK CONSUMER HEALTHCARE TO BE CALLED HALEON |
22 Feb 2022 |
22 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Feb 2022 |
18 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE |
18 Feb 2022 |
18 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Feb 2022 |
17 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Feb 2022 |
17 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Feb 2022 |
17 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Feb 2022 |
17 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
17 Feb 2022 |
17 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Feb 2022 |
16 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Feb 2022 |
14 Feb 2022 |
001-15170 |
| SC 13G |
Open Document
|
Open Filing |
SC 13G |
14 Feb 2022 |
|
005-84251 |
| 6-K |
Open Document
|
Open Filing |
TRANSFER OF TREASURY SHARES |
14 Feb 2022 |
14 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Feb 2022 |
11 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Feb 2022 |
11 Feb 2022 |
001-15170 |
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO SC 13G |
10 Feb 2022 |
|
|
| SC 13G |
Open Document
|
Open Filing |
SCHEDULE 13G |
10 Feb 2022 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO SC 13G |
10 Feb 2022 |
|
|
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
10 Feb 2022 |
|
|
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13G |
10 Feb 2022 |
|
|
| 6-K |
Open Document
|
Open Filing |
BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS |
10 Feb 2022 |
10 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FINAL RESULTS |
09 Feb 2022 |
09 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Feb 2022 |
09 Feb 2022 |
001-15170 |
| SC 13G/A |
Open Document
|
Open Filing |
|
07 Feb 2022 |
|
005-84251 |
| 6-K |
Open Document
|
Open Filing |
PUBLICATION OF FULL YEAR 2021 RESULTS |
07 Feb 2022 |
07 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD |
02 Feb 2022 |
02 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA |
01 Feb 2022 |
01 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Feb 2022 |
01 Feb 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Jan 2022 |
26 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
20 Jan 2022 |
20 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Jan 2022 |
19 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Jan 2022 |
19 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
19 Jan 2022 |
19 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TONY WOOD APPOINTED CSO DESIGNATE, GSK |
19 Jan 2022 |
19 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Jan 2022 |
18 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
18 Jan 2022 |
18 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
UPDATE - GSK CONSUMER HEALTHCARE |
18 Jan 2022 |
18 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Jan 2022 |
14 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jan 2022 |
13 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Jan 2022 |
11 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES |
11 Jan 2022 |
11 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
04 Jan 2022 |
04 Jan 2022 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Dec 2021 |
23 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Dec 2021 |
22 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE |
21 Dec 2021 |
21 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED |
20 Dec 2021 |
20 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 |
17 Dec 2021 |
17 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE |
15 Dec 2021 |
15 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Dec 2021 |
13 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Dec 2021 |
13 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA |
07 Dec 2021 |
07 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT |
07 Dec 2021 |
07 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT |
02 Dec 2021 |
02 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Dec 2021 |
01 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Nov 2021 |
24 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES |
24 Nov 2021 |
24 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Nov 2021 |
23 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS |
17 Nov 2021 |
17 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
15 Nov 2021 |
15 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB |
12 Nov 2021 |
12 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Nov 2021 |
12 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
10 Nov 2021 |
10 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT |
05 Nov 2021 |
05 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Nov 2021 |
01 Nov 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
3RD QUARTER RESULTS |
27 Oct 2021 |
27 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
27 Oct 2021 |
27 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTORATE CHANGE |
27 Oct 2021 |
27 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Oct 2021 |
15 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Oct 2021 |
14 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Oct 2021 |
14 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Oct 2021 |
13 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2021 |
12 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2021 |
12 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2021 |
12 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2021 |
12 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Oct 2021 |
12 Oct 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Oct 2021 |
01 Oct 2021 |
001-15170 |
| SC 13G/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13G |
27 Sep 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Sep 2021 |
24 Sep 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
22 Sep 2021 |
22 Sep 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR DECLARATION |
20 Sep 2021 |
20 Sep 2021 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
16 Sep 2021 |
|
|
| SC 13D/A |
Open Document
|
Open Filing |
AMENDMENT TO FORM SC 13D |
16 Sep 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Sep 2021 |
13 Sep 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Sep 2021 |
09 Sep 2021 |
001-15170 |
| UPLOAD |
Open Document
|
Open Filing |
|
08 Sep 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
07 Sep 2021 |
07 Sep 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
03 Sep 2021 |
03 Sep 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Sep 2021 |
01 Sep 2021 |
001-15170 |
| CORRESP |
Open Document
|
Open Filing |
|
31 Aug 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL |
31 Aug 2021 |
31 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Aug 2021 |
25 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
23 Aug 2021 |
23 Aug 2021 |
001-15170 |
| UPLOAD |
Open Document
|
Open Filing |
|
18 Aug 2021 |
|
|
| 6-K/A |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING - AMENDMENT |
13 Aug 2021 |
13 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Aug 2021 |
11 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Aug 2021 |
11 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING APPLICATION |
05 Aug 2021 |
05 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
02 Aug 2021 |
02 Aug 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
2ND QUARTER RESULTS |
28 Jul 2021 |
28 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Jul 2021 |
28 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Jul 2021 |
26 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD COMMITTEE CHANGES |
23 Jul 2021 |
23 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY |
22 Jul 2021 |
22 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS |
16 Jul 2021 |
16 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
16 Jul 2021 |
16 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
15 Jul 2021 |
15 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Jul 2021 |
14 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
14 Jul 2021 |
14 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jul 2021 |
13 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 Jul 2021 |
13 Jul 2021 |
001-15170 |
| SC 13G |
Open Document
|
Open Filing |
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP |
12 Jul 2021 |
|
|
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jul 2021 |
07 Dec 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
12 Jul 2021 |
12 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Jul 2021 |
09 Jul 2021 |
001-15170 |
| 4 |
Open Document
|
Open Filing |
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP |
06 Jul 2021 |
02 Jul 2021 |
001-40545 |
| 3 |
Open Document
|
Open Filing |
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP |
06 Jul 2021 |
29 Jun 2021 |
001-40545 |
| 6-K |
Open Document
|
Open Filing |
GSK AND ALECTOR COLLABORATION IN IMMUNO-NEUROLOGY |
02 Jul 2021 |
02 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
ELLIOTT ADVISORS (UK) LETTER TO GSK |
02 Jul 2021 |
02 Jul 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jul 2021 |
01 Jul 2021 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
25 Jun 2021 |
31 Dec 2020 |
001-15170 |
| 11-K |
Open Document
|
Open Filing |
ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE |
25 Jun 2021 |
31 Dec 2020 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
25 Jun 2021 |
25 Jun 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 Jun 2021 |
24 Jun 2021 |
001-15170 |
| 4 |
Open Document
|
Open Filing |
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES |
23 Jun 2021 |
21 Jun 2021 |
001-40502 |
| 6-K |
Open Document
|
Open Filing |
GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE |
23 Jun 2021 |
23 Jun 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT |
22 Jun 2021 |
22 Jun 2021 |
001-15170 |
| 3 |
Open Document
|
Open Filing |
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES |
17 Jun 2021 |
16 Jun 2021 |
001-40502 |
| 6-K |
Open Document
|
Open Filing |
GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448 |
14 Jun 2021 |
14 Jun 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 Jun 2021 |
11 Jun 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
09 Jun 2021 |
09 Jun 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TRC CAPITAL LETTER |
04 Jun 2021 |
04 Jun 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
01 Jun 2021 |
01 Jun 2021 |
001-15170 |
| SD |
Open Document
|
Open Filing |
SD |
27 May 2021 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
27 May 2021 |
27 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SANOFI AND GSK INITIATE NEW PHASE 3 CLINICAL STUDY |
27 May 2021 |
27 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK/VIR SOTROVIMAB FDA EMERGENCY USE AUTHORIZATION |
27 May 2021 |
27 May 2021 |
001-15170 |
| SC 13D/A |
Open Document
|
Open Filing |
AMENDED SCHEDULE 13D |
25 May 2021 |
|
|
| 4 |
Open Document
|
Open Filing |
CHANGES IN BENEFICIAL OWNERSHIP |
24 May 2021 |
20 May 2021 |
000-30319 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
24 May 2021 |
24 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
GSK/VIR SOTROVIMAB RECEIVES POSITIVE EMA OPINION |
21 May 2021 |
21 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BLOCK LISTING INTERIM REVIEW |
18 May 2021 |
18 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS |
18 May 2021 |
18 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
SANOFI/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS |
17 May 2021 |
17 May 2021 |
001-15170 |
| 25-NSE |
Open Document
|
Open Filing |
|
14 May 2021 |
|
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
13 May 2021 |
13 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
11 May 2021 |
11 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
EMTN PROSPECTUS |
11 May 2021 |
11 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
BOARD AND COMMITTEE CHANGES |
06 May 2021 |
06 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
RESULT OF AGM |
05 May 2021 |
05 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
TOTAL VOTING RIGHTS |
04 May 2021 |
04 May 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
28 Apr 2021 |
28 Apr 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
1ST QUARTER RESULTS |
28 Apr 2021 |
28 Apr 2021 |
001-15170 |
| 6-K |
Open Document
|
Open Filing |
DIRECTOR/PDMR SHAREHOLDING |
26 Apr 2021 |
26 Apr 2021 |
001-15170 |